MARPE in Patients With Cleft Lip and Palate

NCT ID: NCT04354116

Last Updated: 2020-09-16

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

44 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-01-10

Study Completion Date

2021-09-10

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The objective of this randomized controlled study will be to evaluate the dental and skeletal effects of maxillary protraction with a facemask, associated with MARPE and Class III elastics in patients with unilateral cleft lip and palate (CLP) with maxillary retrusion, compared to HYRAX type maxillary expanders. The investigators will examine differences in treatment times, along with skeletal, dental and soft tissue changes.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The CONSORT statement will be used as a guide for this study. This work will be a parallel group study, randomized, with active control, with an allocation ratio of 1: 1.

This study was submitted to the Research Ethics Committee of the Pontifical Catholic University of Minas Gerais. Participants will be recruited in the Master's Degree in Orthodontics at PUC Minas, based on inclusion criteria.

Interventions:

Palatal expanders of the HYRAX type, with bands on the first permanent molars or second deciduous molars will be used for patients in both groups. The hooks for the use of Class III elastics will be welded on the vestibular of the upper molar bands. In the experimental group, the expander will be anchored mesially and bilaterally in mini-implants, in a technique known as rapid maxillary expansion assisted by mini-implants (MARPE). The control group will be active, with conventional dento-mucus-supported HYRAX expanders. All expanders will be manufactured by the same orthodontic technician.

Both groups will be treated with maxillary protraction with a Petit-type face mask at night (12 hours a day). The direction of the elastics for the maxillary traction force will be between 15˚ to 30˚ below the occlusal plane, providing a force between 400 and 500 g per side. During the day (12 hours a day), patients will use a lower expansion plate with an occlusal stop, which will be activated once a week (0.25 mm), with hooks in the region of the lower canines for the use of Class III elastics. size 3/16 "(150g). The time-frame of the experiment will be 6 months.

Results (primary and secondary) The primary outcome will be the degree of anterior movement of the maxilla after treatment). Secondary outcomes will be changes in other cephalometric variables and treatment time.

Conical beam computed tomography (CBCT) will be performed at the beginning and at the end of the treatment. Teleradiographies will be extracted from the CFFCs and cephalometric measurements will be obtained by the investigator (V.E.) using the Dolphin Image software (Austin, USA). Traditional cephalometric measurements will be used to describe the changes before and after treatment.

Calculation of the sample size As no study in the orthodontic literature used the same protocol used in this study, the sample size will be estimated by G \* Power (version 3.0.8), with 95% power; significance level of 5%; two-tailed. For point A, sagittal movements of 2.6 +/- 1.5 mm in the RME group and 5.8 +/- 2.3 mm in the RME group with constriction, a minimum sample size of 11 in each group will be necessary to detect a significant difference between groups. For ANS, sagittal movements of 2.1 +/- 1.3 mm in the RME group and 4.8 +/- 2.5 mm in the RME group with constriction, a minimum sample size of 16 in each group will be necessary to detect a significant difference between groups. Therefore, 16 will be the minimum sample size for each group. The sample size will be increased by 40%, resulting in 22 patients for each group, in case there is a withdrawal or the need to use a different protocol.

Randomization (random number generation, allocation hiding, implementation) Patients will be recruited and allocated to the control group (RME) or the intervention group (MARPE) according to the sequence of participation. Simple randomization will be applied.

Blinding The blinding of investigators or participants will not be possible because the expanders in the two groups will be different. Operators and patients will easily know which group they are in. However, blinding will be used during cephalometric analysis. All image exams will be hidden by opaque tape and replaced with research numbers and then mixed together before analysis. The investigator will not know the clustering of the CT scans, which will look similar.

Statistical analysis (primary and secondary results, subgroup analyzes) All statistical analyzes will be performed using the software (version 18.0; PASW Statistics, Chicago, Illinois). Descriptive statistics will include the means and standard deviations of age, total treatment time, maxillary prostration time, cephalometric values and changes in values in each group. The 1-sample Kolmogorov-Smirnov test will be used to test the normality of distributions for all times and differences in cephalometric values. Independent t-tests will be used to compare the two groups, including total treatment time, protraction time and changes in cephalometric values; the t-tests will be used for the values that show "equality of variances not assumed" between the groups (SNA and Nasio perpendicular). The level of significance will be 0.05, with two-tailed test.

Error of the Method All locations and measurements of the points will be checked twice carefully at the end of the initial plots and measurements. Not all images will be traced twice. However, to evaluate the tracing errors, 20 scans will be chosen at random. Plots, locations and measurements will be made twice, two weeks apart and then subjected to the Dahlberg formula. The error of the method will be determined by the Dahlberg formula, where n = 20 and d will be the difference between the measurements in 2 moments.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Palatal Expansion Technique Cleft Lip and Palate Class III Malocclusion Skeletal Malocclusion

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

MARPE

Maxillary expander anchored in mini-implants (MARPE)

Group Type EXPERIMENTAL

Rapid maxillary expansion

Intervention Type DEVICE

Palatal expanders of the HYRAX type, with bands on the first permanent molars will be used for patients in both groups. In the experimental group, the expander will be anchored mesially and bilaterally in mini-implants, in a technique known as rapid maxillary expansion assisted by mini-implants (MARPE). The control active group will be with conventional HYRAX expanders. The maxillary expansion protocol will be once a day for 2 weeks.

Maxillary Protraction

Intervention Type DEVICE

Protraction hooks will be projected around the upper canine area. In the experimental group (MARPE), the appliance will be anchored mesially and bilaterally in mini-implants. The control active group will be anchored with conventional HYRAX expanders. Both groups will be treated with maxillary protraction with a Petit-type face mask at night (12 hours a day).

Hyrax

Tooth-born anchored maxillary expanders, without mini-implants

Group Type ACTIVE_COMPARATOR

Rapid maxillary expansion

Intervention Type DEVICE

Palatal expanders of the HYRAX type, with bands on the first permanent molars will be used for patients in both groups. In the experimental group, the expander will be anchored mesially and bilaterally in mini-implants, in a technique known as rapid maxillary expansion assisted by mini-implants (MARPE). The control active group will be with conventional HYRAX expanders. The maxillary expansion protocol will be once a day for 2 weeks.

Maxillary Protraction

Intervention Type DEVICE

Protraction hooks will be projected around the upper canine area. In the experimental group (MARPE), the appliance will be anchored mesially and bilaterally in mini-implants. The control active group will be anchored with conventional HYRAX expanders. Both groups will be treated with maxillary protraction with a Petit-type face mask at night (12 hours a day).

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Rapid maxillary expansion

Palatal expanders of the HYRAX type, with bands on the first permanent molars will be used for patients in both groups. In the experimental group, the expander will be anchored mesially and bilaterally in mini-implants, in a technique known as rapid maxillary expansion assisted by mini-implants (MARPE). The control active group will be with conventional HYRAX expanders. The maxillary expansion protocol will be once a day for 2 weeks.

Intervention Type DEVICE

Maxillary Protraction

Protraction hooks will be projected around the upper canine area. In the experimental group (MARPE), the appliance will be anchored mesially and bilaterally in mini-implants. The control active group will be anchored with conventional HYRAX expanders. Both groups will be treated with maxillary protraction with a Petit-type face mask at night (12 hours a day).

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with cleft lip and palate;
* 6 to 13 years before orthodontic treatment, with sagittal deficiency of the facial middle third;
* Angle Class III malocclusion, or mesial step of the deciduous second molars, and anterior crossbite;
* ANB less than 0˚, Wits less than -2 mm and the distance from point A to the perpendicular nasion less than 0 mm.

Exclusion Criteria

* Previous orthodontic treatment;
* Other craniofacial anomalies;
* Inadequate maxillary denture for placement of a expander.
Minimum Eligible Age

6 Years

Maximum Eligible Age

13 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Pontifícia Universidade Católica de Minas Gerais

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Ildeu Andrade Jr.

Principal Investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Ildeu Andrade Jr., PhD

Role: PRINCIPAL_INVESTIGATOR

Pontifícia Universidade Católica de Minas Gerais

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Pontifical Catholic University of Minas Gerais

Belo Horizonte, Minas Gerais, Brazil

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Brazil

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Vitor Eto, DDS

Role: CONTACT

55(31)99822-5804

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Ildeu Andrade Jr., PhD

Role: primary

3319-4416

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

MARPE Class III cleft patients

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Effect of Serum Vitamin D on MARPE Treatment Response
NCT06943443 ENROLLING_BY_INVITATION NA
Effects of AlignBabyCleft (ABaCleft)
NCT05357092 NOT_YET_RECRUITING NA